GreenBytes Wards Off Germs and Costly Comput...(. ...),Health
Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
GreenBytes Wards Off Germs and Costly Computer Repairs
Date:5/26/2009
>.
'/>"/>
| SOURCE GreenBytes Copyright©2009 PR Newswire. All rights reserved |
Related medicine technology :
1. Michael J. Fox Foundation Awards $2.1 Million to Improve Drug Delivery in Parkinsons Disease
2. Parkinsons Disease Foundation Awards $300,000 in Bridge Funding for Innovative Research Projects
3. Michael J. Fox Foundation Awards $2.9 Million for Two New Parkinsons Disease Clinical Trials
4. Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinsons Disease Research
5. Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA(R) (tocilizumab)
6. Premier Research Honored as Clinical Research Team of the Year at 2008 GCPj Awards
7. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
8. Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl(R) to Further Help Prostate Cancer Patients
9. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
10. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
11. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
Post Your Comments:
Breaking Medicine Technology:RetireSafe Announces Intention to Key Vote Senator Dorgan's Drug Importation Amendment (SA 2793) 2Dynatronics Receives 180-Day NASDAQ Extension 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3Abbott Declares 343rd Consecutive Quarterly Dividend 14129 1Medical Device Manufacturer MRPC Awarded ISO 13485 Certification 57543 1Medical Device Manufacturer MRPC Awarded ISO 13485 Certification 57543 2Global Med Technologies Inc s CEO to Make Major New Product Announcement the Morning of the LDV Investor Conference and Will Demo the Product on Wedn 57541 1Global Med Technologies Inc s CEO to Make Major New Product Announcement the Morning of the LDV Investor Conference and Will Demo the Product on Wedn 57541 2Global Med Technologies Inc s CEO to Make Major New Product Announcement the Morning of the LDV Investor Conference and Will Demo the Product on Wedn 57541 3
[0] RetireSafe Announces Intention to Key Vote Senator Dorgan's Drug Importation Amendment (SA 2793)[0] Dynatronics Receives 180-Day NASDAQ Extension[0] Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug
Other Medicine Technology:Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 2Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 3Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 4Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 5Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 6Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 7Study Results Present Paradigm Shift; REDUCE Trial Shows New Hope for the Risk Reduction of Prostate Cancer 2
Breaking Medicine News(10 mins):Health News:MRI Partners with Natural Marketing Institute 2Health News:MRI Partners with Natural Marketing Institute 3Health News:MRI Partners with Natural Marketing Institute 4Health News:Planview and Carestream Health Discuss the Intelligent Portfolio on December 17 Webinar 2Health News:Planview and Carestream Health Discuss the Intelligent Portfolio on December 17 Webinar 3Health News:FEHBP Open Enrollment Period to be Discussed on Special Rebroadcast of 'Inside Government' 2Health News:Pelosi: Lifting the Ban on Federal Funding for Syringe Exchange is a Victory for Science and for Public Health 2
[1] MRI Partners with Natural Marketing Institute[0] University of Maryland chemist receives Astellas Award for blindness prevention research[0] Planview and Carestream Health Discuss the Intelligent Portfolio on December 17 Webinar [0] FEHBP Open Enrollment Period to be Discussed on Special Rebroadcast of 'Inside Government'[0] Pelosi: Lifting the Ban on Federal Funding for Syringe Exchange is a Victory for Science and for Public Health
Other Medicine News:Health News:eDiets.com(R) Announces Q3 2008 Results 2Health News:eDiets.com(R) Announces Q3 2008 Results 3Health News:eDiets.com(R) Announces Q3 2008 Results 4Health News:eDiets.com(R) Announces Q3 2008 Results 5Health News:eDiets.com(R) Announces Q3 2008 Results 6Health News:eDiets.com(R) Announces Q3 2008 Results 7Health News:Pelvic Inflammation Puts Girls at Risk for Repeat STIs 2Health News:Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer 2Health News:Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer 3Health News:Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer 4Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 2Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 3Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 4Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 5Health News:Leading Scientists From Around the World Headed to Kansas for Symposium on Combating Deadly Infectious Diseases 2Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 2Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 3Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 4
eDiets.com(R) Announces Q3 2008 ResultsPelvic Inflammation Puts Girls at Risk for Repeat STIsWatson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate CancerTop NY Court Blinks in 'First Department' WPP Discrimination Power PlayLeading Scientists From Around the World Headed to Kansas for Symposium on Combating Deadly Infectious Diseases FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia – Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |